Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 15/20 | 0.41 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.37 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26067407 | 0.94 | CDK4 (0.40) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL25259911 | 0.83 | PDE10A (0.42) | PDE10ADHFR | |
| SCHEMBL25840823 | 0.83 | PDE10A (0.40) | PDE10ADHFR | |
| SCHEMBL25259058 | 0.83 | PDE10A (0.41) | PDE10ADHFR | |
| SCHEMBL25840830 | 0.82 | PDE10A (0.41) | PDE10ASMPD3DHFR | |
| SCHEMBL25840815 | 0.82 | PDE10A (0.41) | PDE10ADHFR | |
| SCHEMBL25303229 | 0.82 | PDE10A (0.41) | PDE10ADHFR | |
| SCHEMBL25840911 | 0.80 | PDE10A (0.41) | PDE10ADHFR | |
| SCHEMBL25841373 | 0.80 | PDE10A (0.41) | PDE10ADHFR | |
| SCHEMBL25840846 | 0.80 | PDE10A (0.41) | PDE10ADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522619-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4463462-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118715231-A | Complement factor inhibitors and uses thereof | 安尼艾克松股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2023137166-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023137166-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | CDK4 4130/4885CCNA2 3758/4885CCND1 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.